SOLICITED REVIEW

Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: Management

Dong Il Park,* Tadakazu Hisamatsu,† Minhu Chen,‡ Siew Chien Ng,§ Choon Jin Ooi,¶ Shu Chen Wei,** Rupa Banerjee,†† Ida Normiha Hilmi,‡‡ Yoon Tae Jeen, §§ Dong Soo Han,¶¶ Hyo Jong Kim,*** Zhihua Ran,††† Kaichun Wu,‡‡‡ Jiaming Qian,‡‡‡‡ Pin-Jin Hu,¶¶¶ Katsuyoshi Matsuoka,¶¶¶¶ Akira Andoh,***** Yasuo Suzuki,†††† Kentaro Sugano,‡‡‡‡ Mamoru Watanabe,¶¶¶¶ Toshifumi Hibi,‡‡‡‡‡ Amarender S Puri¶¶¶¶¶ and Suk-Kyun Yang*****

*Department of Internal Medicine, Kangbuk Samsung Hospital Sungkyunkwan University, †Department of Internal Medicine, Korea University, ‡Division of Medicine, Department of Internal Medicine, Kyung Hee University, §§ Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, §§ Department of Internal Medicine, Hanyang University Guri Hospital, Seoul, Gunggi, Korea, ¶¶ The Third Department of Internal Medicine, Kyorin University School of Medicine, ¶¶¶ Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, ¶¶¶¶ Center for Advanced IBD Research and Treatment, Kitasato University, Tokyo, ¶¶¶¶¶ Department of Gastroenterology, Shiga University, Otsu, ¶¶¶¶¶¶ Department of Internal Medicine, Toho University, Sakura, ¶¶¶¶¶ Department of Medicine, Jichi Medical University, Tochigi, Japan, ¶¶ Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, ¶¶¶ Department of Gastroenterology, Shanghai Jiao Tong University, Shanghai, ¶¶¶¶Department of Gastroenterology, Fourth Military Medical University, Xi’an, ¶¶¶¶¶ Department of Gastroenterology, Peking Union Medical College, Beijing, China, ¶¶ Department of Medicine and Therapeutics, Institute of Digestive Disease, LKS Institute of Health Science, State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong; ‡‡‡‡‡ Gleneagles Medical Centre and Duke-NUS Medical School, Singapore; ** Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan; ¶¶¶ Department of Medical Gastroenterology, Asian Institute of Gastroenterology, Hyderabad, ¶¶¶¶ Department of Gastroenterology, GB Pant Institute of Postgraduate Medical Education and Research, New Delhi, India; and ¶¶¶¶Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia

Key words
anti-TNF, consensus statement, inflammatory bowel disease, tuberculosis.

Accepted for publication 5 October 2017.

Correspondence
Dr Suk-Kyun Yang, Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea. Email: sky@amc.seoul.kr

These consensus statements were developed and approved by the AOCCC and APAGE and are being published simultaneously in the Journal of Gastroenterology and Hepatology and Intestinal Research.

Financial support: This study was supported by a grant from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A120176).

Abstract

Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in this region. Thus, the Asian Organization for Crohn’s and Colitis and the Asia Pacific Association of Gastroenterology have developed a set of consensus statements about risk assessment, detection and prevention of latent TB infection, and management of active TB infection in patients with inflammatory bowel disease (IBD) receiving anti-TNF treatment. Twenty-three consensus statements were initially drafted and then discussed by the committee members. The quality of evidence and the strength of recommendations were assessed by using the Grading of Recommendations Assessment, Development, and Evaluation methodology. Web-based consensus voting was performed by 211 IBD specialists from nine Asian countries concerning each statement. A consensus statement was accepted if at least 75% of the participants agreed. Part 2 of the statements comprised three parts: (3) management of latent TB in preparation for anti-TNF therapy, (4) monitoring during anti-TNF therapy, and (5) management of an active TB infection after anti-TNF therapy. These consensus statements will help clinicians optimize patient outcomes by reducing the morbidity and mortality related to TB infections in patients with IBD receiving anti-TNF treatment.

Introduction

Part 2 of the Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment focused on management of latent tuberculosis (TB) in preparation for anti-tumor necrosis factor (TNF) therapy, monitoring during anti-TNF therapy, and management of an active TB infection after anti-TNF therapy. As with Part 1, the quality of evidence and the strength of recommendations were assessed by using the Grading of Recommendations Assessment, Development, and Evaluation methodology. A consensus statement was accepted if at least 75% of the participants agreed.
Management of latent TB in preparation for anti-TNF therapy

**All patients with IBD diagnosed as having latent TB should be treated with a therapeutic regimen for latent TB before the initiation of anti-TNF therapy**

(Quality of evidence: moderate/Recommendations: strong)

(Level of agreement: Strongly agree 55%, Agree 37%, Uncertain 3%, Disagree 3%, Strongly disagree 2%)

Anti-TNF therapies are associated with a 2- to 8-fold increased risk of active TB in patients receiving them compared with that in the general population.1–4 Moreover, the risk of active TB was further increased when anti-TNF was used in combination with other immunosuppressants compared with that when anti-TNF monotherapy was used.5 Most of the active TB cases occurred within 3–4 months after anti-TNF therapy initiation; thus, reactivation of latent TB infection (LTBI) is considered to be the main cause rather than a new infection.1 For these reasons, screening and treatment for LTBI before initiating anti-TNF therapy are strongly recommended by many scientific organizations and health authorities worldwide.5–19

The strict recommendation of chemoprophylaxis for LTBI has reduced the incidence of new TB cases among infliximab users from 11 patients in the first 2000 infliximab users to only two patients in the second 2000 registrants.20 Therefore, to reduce the risk of active TB, all patients with inflammatory bowel disease (IBD) diagnosed as having LTBI should be treated with a therapeutic regimen for latent TB before initiating anti-TNF therapy.

**Chemotherapy for LTBI is not necessary for individuals with a history of proper treatment of TB unless there is a suspicion of a newly acquired infection**

(Quality of evidence: low/Recommendations: weak)

(Level of agreement: Strongly agree 24%, Agree 63%, Uncertain 10%, Disagree 3%)

Because patients who had completed a full course of anti-TB treatment in the past do not seem to have an increased risk of developing TB while receiving anti-TNF therapy, tests for a TB infection are not considered to have significant clinical meaning, and LTBI treatment is not generally recommended unless there is a suspicion of a newly acquired TB infection.15,17 In a French study, even the reinitiation of anti-TNF after appropriate anti-TB treatment did not induce a reactivation of Mycobacterium tuberculosis (MTB) during the mean follow-up period of 42.7 months (range: 18–60 months) in patients with TB as a complication of anti-TNF therapy.21 Therefore, the decision to treat LTBI in these patients should depend on a new contact history with patients with active TB. When the appropriateness of prior anti-TB treatment is unclear, the decision to treat LTBI depends on the physician.15 In cases with a history of inappropriate anti-TB treatment, the possibility of active TB should be excluded before the initiation of LTBI treatment.15

**The recommended treatment regimens for LTBI may vary among different countries**

(Quality of evidence: low/Recommendations: weak)

(Level of agreement: Strongly agree 35%, Agree 63%, Uncertain 1%, Disagree 1%)

To date, the effectiveness of various treatment regimens for LTBI has not been evaluated in prospective controlled trials. The recommended treatment regimens for LTBI may vary according to specific geographic areas or the patient’s epidemiological background. Daily isoniazid (INH) for 12 months and daily INH plus rifampicin (RFP) for 3 months exhibited the best clinical efficacy, providing patients with > 90% protection.17 However, daily INH for 9 months is considered the standard regimen for treating LTBI in many countries, including Australia,22 Canada,14 France,23 Japan,10 Korea,19 Spain,24 and Switzerland.25 Moreover, randomized trials have shown that after the successful completion of daily INH for 9 and 6 months, the protection rates against TB reactivation were approximately 90% and 60–80%, respectively.26 The major disadvantage of 9-month daily INH is poor compliance owing to the long duration of treatment and hepatotoxicity.27

Recently, shorter regimens such as daily RFP for 4 months or daily INH plus RFP for 3 months are being aggressively studied to improve the treatment completion rate.27,28 Currently, 4 months of daily RFP is recommended as a second-line therapy in the United States, Japan, and Saudi Arabia,8,26,29 whereas 3 months of daily INH plus RFP is recommended in the United Kingdom,16 based on long-term experience.27,28 Three months of daily INH plus RFP and 4 months of daily RFP are recommended as an alternative treatment to daily INH for 9 months in South Korea.19 Because both INH and RFP may be associated with hepatotoxicity, underlying liver diseases should be assessed before initiating LTBI treatment. Two months of daily RFP plus pyrazinamide was recommended as an LTBI treatment strategy in the year 2000 in the United States.26 However, this combination was subsequently excluded as an approved LTBI treatment strategy after several reports of deaths resulting from severe liver toxicity.30 Although 3 months of a daily combination of INH plus rifapentine (once a week for a total of 12 intermittent treatment sessions) has been approved and recommended for treating LTBI in the United States since 2011, rifapentine is not yet available in many countries.31

Even after LTBI is treated before commencing anti-TNF therapy, active TB may develop during the course of treatment. For this reason, the decision to treat LTBI should be readdressed after contact with patients with active TB again. The treatment regimen for LTBI in this case should be decided based on the drug sensitivity results of the index case (patient with active TB).19

In summary, treatment options recommended for LTBI include 6 months of daily INH, 9 months of daily INH, 3 months of weekly rifapentine plus INH, 3–4 months of daily INH plus RFP, or 3–4 months of daily RFP alone.32 The recommended treatment regimens for LTBI may vary among different countries.
When latent TB is found in patients with IBD who are planned for anti-TNF therapy, it should be postponed for at least 3 weeks after commencing LTBI treatment; however, the simultaneous initiation of LTBI and anti-TNF therapies may be considered in urgent cases.

(Quality of evidence: low/Recommendations: weak)

(Level of agreement: Strongly agree 18%, Agree 63%, Uncertain 16%, Disagree 2%, Strongly disagree 1%)

Many experts suggest that the time interval between the commencement of LTBI treatment and initiation of anti-TNF therapy is dependent on the patient’s individual risk of TB reactivation and their urgent need for anti-TNF therapy to control disease activity. In general, most of the guidelines recommend starting anti-TNF 3–4 weeks after initiating LTBI prophylaxis; however, no large cohort studies have been conducted on the optimal time interval between the initiation of LTBI treatment and anti-TNF therapy. This recommendation is based on the observation that starting anti-TNF therapy 1 month after LTBI prophylaxis in LTBI-positive patients with rheumatoid arthritis significantly reduced the risk of TB reactivation. Furthermore, some experts recommend that if the activity of underlying disease and the global status of the patient permit, waiting for one additional month may be more beneficial because most of the adverse effects caused by INH treatment occur within the first 2 months of therapy. However, in case of greater clinical urgency or with specialist recommendations to avoid surgical intervention, the simultaneous initiation of LTBI and anti-TNF therapy may be considered based on a shared decision-making between the patient and physician, after an informed discussion of the benefits and risks; however, evidence for this practice is currently unavailable.

Monitoring during anti-TNF therapy

Even after LTBI is treated before initiating anti-TNF therapy, active TB may develop during anti-TNF therapy.

(Quality of evidence: moderate/Recommendations: weak)

(Level of agreement: Strongly agree 25%, Agree 62%, Uncertain 12%, Disagree 1%)

It has been observed that the treatment of LTBI before starting anti-TNF therapy reduces the risk of MTB reactivation. Randomized trials have shown that after the successful completion of a 9- and 6-month daily INH treatment, the protection rates against MTB reactivation were approximately 90% and 60–80%, respectively. However, concerns about the risk of active TB infection among anti-TNF users, even after LTBI treatment, remain. The clustering of TB reports shortly after the initiation of anti-TNF therapy is consistent with the reactivation of LTBI owing to incomplete TB eradication with the currently recommended regimens, especially for INH-resistant MTB.

Patients with IBD undergoing anti-TNF therapy should be regularly monitored for symptoms and signs suggesting the development of active TB.

(Quality of evidence: moderate/Recommendations: strong)

(Level of agreement: Strongly agree 67%, Agree 30%, Uncertain 3%)

The development of active TB cannot be completely prevented during anti-TNF therapy despite LTBI treatment owing to the reactivation of LTBI caused by incomplete TB eradication with the currently recommended regimens and the risk of new infections resulting from close contact with infectious patients with TB in countries with a high prevalence of TB, even after the successful eradication of LTBI. Occasionally, active TB can be detected as an incidental finding on a chest radiograph during a regular check-up in asymptomatic patients. For this reason, the development of TB during anti-TNF therapy should carefully be monitored.

Although the negative conversion of interferon gamma release assay (IGRA) is observed in some patients, most of the patients with positive tuberculin skin test (TST) or IGRA results at baseline will have positive test results even after the successful treatment of LTBI. Currently, there is no method of confirming whether LTBI has been adequately cured after the completion of LTBI treatment. Therefore, monitoring should be based only on clinical symptoms and the signs of recurrent TB. The most frequent symptoms at the presentation of TB are fever, weight loss, respiratory symptoms, enlarged lymph nodes, and fatigue. Because more than half of these patients present with extrapulmonary or disseminated disease, abdominal pain, diarrhea, ascites, dysphonia, and headache may be the presenting symptoms. Therefore, a high level of clinical attention should be paid to patients with typical symptoms, such as an unexplained fever with or without weight loss, and those with atypical symptoms, to avoid a delay in diagnosis. Most anti-TNF-related TB cases occur within 3–6 months after initiating anti-TNF therapy. Thus, a short-term, regular follow-up to monitor symptoms and signs is critical during the first several months in these patients.
In patients without LTBI before anti-TNF therapy, an annual TST and/or IGRA are recommended in the Canadian, Italian, Swiss, and US guidelines, especially in patients with a high risk for MTB infection. Serial TST and IGRA testing may be useful to identify initial false-negative cases of LTBI and new TB infections during long-term anti-TNF therapy, especially in areas with a high TB burden. In addition, the risk of TST (+) conversion was found to significantly increase during 3 years of anti-TNF therapy. To minimize this problem, some experts emphasize repeating the TST or IGRA tests annually for patients on long-term anti-TNF therapy. However, the necessity of regular TB infection tests is not universally recommended at present.

**Exposure to active TB during anti-TNF therapy should prompt reevaluation for active TB or LTBI**

(Quality of evidence: low/Recommendations: strong)

(Level of agreement: Strongly agree 44%, Agree 52%, Uncertain 4%)

Patients with IBD receiving anti-TNF therapy who have close contact with infectious patients with TB have a high risk of developing active TB or LTBI. Therefore, studies for diagnosing active TB and LTBI should be immediately performed in these patients.

Chest radiography should be performed to exclude active TB regardless of typical or atypical TB symptoms. Performing a retest has no clinical relevance for patients who were already positive for TST or IGRA before starting anti-TNF therapy, and the decision to start LTBI treatment should be based on only the clinical factors of these patients. If the MTB infection tests were negative before starting anti-TNF therapy, a re-test should be performed immediately to confirm a positive conversion. However, in most cases, TB infection tests need to be repeated 8–10 weeks after close contact with infectious patients with TB because positive conversion takes 2–10 weeks (window period) after TB infection. Moreover, LTBI treatment should be initiated during this window period.

**Compared with TB in the general population, patients who develop TB while on anti-TNF therapy have mostly severe and atypical disease, exhibiting a higher probability of extrapulmonary and disseminated manifestations**

(Quality of evidence: low/Recommendations: strong)

(Level of agreement: Strongly agree 27%, Agree 55%, Uncertain 16%, Disagree 2%)

**Mycobacterium tuberculosis** infection in patients undergoing anti-TNF therapy is more commonly extrapulmonary and disseminated compared with that in the general population. The physiopathology of disseminated TB may help understand this phenomenon. Alveolar macrophages, contaminated by MTB during the infectious process, induce the production of TNF-α. TNF-α is a key protective cytokine against MTB that, together with TNF-dependent chemokines, plays a critical role in the process of granuloma formation, preventing the dissemination of MTB. After the initiation of anti-TNF therapy, the process of granuloma formation is impaired, promoting the dissemination and reactivation of MTB.

In the general population, <20% of TB cases represent extrapulmonary forms and only 2% of patients exhibit disseminated disease. However, when TB occurs in patients on anti-TNF therapy, up to 60% represent extrapulmonary forms and approximately 25% of patients exhibit disseminated disease. Furthermore, the mortality rate has been reported to be as high as 17% in these patients.

**Management of active TB infection after anti-TNF therapy**

If active TB is diagnosed during anti-TNF therapy, anti-TNF therapy should be withheld, and anti-TB therapy should be commenced.

(Quality of evidence: low/Recommendations: strong)

(Level of agreement: Strongly agree 48%, Agree 45%, Uncertain 4%, Disagree 3%)

If active TB develops during anti-TNF therapy, anti-TNF therapy should be withheld and anti-TB therapy should be commenced; however, the British guidelines recommend that anti-TNF therapy can be continued if clinically indicated because the patient would otherwise be prevented from receiving the continued clinical benefit to their underlying disease and may experience a flare-up or major clinical deterioration.

Although there are little data on the impact of immunomodulators on the risk of TB in patients also receiving anti-TNF therapy, the results from a small case-control study in patients with rheumatoid arthritis revealed that the risk of active TB among corticosteroid, thiopurine, or methotrexate users was not increased. This suggests that these medications do not need to be discontinued during anti-TB therapy, although larger studies are warranted.

The optimal duration of anti-TB therapy for active TB that occurs during anti-TNF therapy has not been well defined. Moreover, there is no evidence that the duration of anti-TB therapy needs to be prolonged if active TB occurs during anti-TNF therapy. Therefore, the duration of treatment for active TB that occurs during anti-TNF therapy is not different from that of ordinary TB.
It is considered safe to delay the resumption of anti-TNF therapy until the completion of anti-TB therapy; however, anti-TNF therapy may be restarted after 2 months of anti-TB therapy if patients demonstrate a favorable response to anti-TB therapy and require the early resumption of anti-TNF therapy.

(Quality of evidence: low/Recommendations: weak)

(Level of agreement: Strongly agree 12%, Agree 65%, Uncertain 19%, Disagree 4%)

Although there have been no prospective or controlled studies on the ideal timing of initiating anti-TNF therapy once anti-TB therapy has been initiated, it is considered safe to delay the resumption of anti-TNF therapy until the completion of anti-TB therapy. However, the reinitiation of anti-TNF therapy may be considered after 2 months of intensive anti-TB therapy if the patients satisfy all of the following conditions: TB was not initially severe; patients demonstrated a favorable response to anti-TB therapy; drug susceptibility is proven; and there is an urgent need for the early resumption of anti-TNF therapy.7,58 In two retrospective cohort studies, there were neither complications in the TB course nor cases of TB relapse after the early retreatment with anti-TNF after initiating anti-TB therapy in patients with IBD with active TB during anti-TNF therapy.59 Theoretically, if anti-TB therapy was appropriately performed, the associated immunosuppressed state should not interfere with the response to anti-TB therapy but rather accelerate the sputum culture conversion.59,60 However, there remain insufficient data in this regard.

Paradoxical reaction comprising a favorable response of MTB to anti-TB medication but worsening of the clinical, biological, or radiological findings of TB owing to an enhanced immune response can occur within a few months after the initiation of anti-TB treatment and anti-TNF withdrawal.

(Quality of evidence: low/Recommendations: weak)

(Level of agreement: Strongly agree 16%, Agree 69%, Uncertain 15%)

A paradoxical reaction, also called immune reconstitution inflammatory syndrome (IRIS), comprising a favorable response of MTB to anti-TB medication but worsening of clinical, biological, or radiological findings of TB, can occur within a few months after the initiation of anti-TB therapy and withdrawal of anti-TNF.51,62 The condition results from the rapid recovery of MTB-specific immune responses by the host after the withdrawal of anti-TNF therapy. In addition, there is a latent period between the initiation of anti-TB therapy and the development of the paradoxical reaction because the effect of anti-TNF will persist for 3–4 weeks after withdrawal.63 The frequency of anti-TNF-associated TB-IRIS in the RATIO registry was 7%; the IRIS-associated factors comprised disseminated TB, a history of MTB exposure, and steroid use at the time of TB diagnosis.64

Although the early diagnosis of IRIS remains difficult, identifying negative conversion is of great importance in patients with bacteriologically confirmed TB.15 Physicians should be aware of this condition because prolonged anti-TB therapy is not required; however, paradoxically, systemic corticosteroid use or the reintroduction of anti-TNF therapy may result in a more favorable outcome in severe cases.65

Conclusions

Routine LTBI screening and prophylactic treatment is currently recommended as the standard of care for patients with IBD who are under consideration for anti-TNF therapy. These consensus statements will help clinicians optimize patient outcomes by reducing the morbidity and mortality related to TB infection in these patients. Further research is required to develop more sensitive and specific tests to detect LTBI without being influenced by immunosuppressive medications and identify more effective and safe regimens for LTBI treatment.

References

1. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 2001; 345: 1098–104.
2. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003; 48: 2122–7.
3. Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologies and tocilizumab: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford) 2014; 53: 1872–85.
4. Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, in inflammatory bowel disease. Gut 2010; 59: 476–83.
5. Lorenzetti R, Zullo A, Ridola L et al. Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials. Ann. Med. 2014; 46: 547–54.
6. Rahier JF, Ben-Horin S, Chowers Y et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J. Crohns Colitis 2009; 3: 47–91.
7. Rahier JF, Magro F, Abreu C et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J. Crohns Colitis 2014; 8: 443–68.
8. Getahun H, Matteelli A, Abubakar I et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur. Respir. J. 2015; 46: 1563–76.
9. Favalli EG, Caporali R, Sinigaglia L et al. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II. Safety. Clin. Exp. Rheumatol. 2011; 29: S15–S27.
10 The Prevention Committee and the Treatment Committee of the Japanese Society for Tuberculosis. Treatment guidelines for latent tuberculosis infection. *Kekkaku* 2014; 89: 21–37.

11 Nordgaard-Lassen I, Dahlerup JF, Belard E et al. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. *Dan. Med. J.* 2012; 59: C4480.

12 Iannone F, Cantini F, Lapadula G. Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: international recommendations. *J. Rheumatol. Suppl.* 2014; 91: 41–6.

13 Carpio D, Jauregui-Amezaga A, de Francisco R et al. Tuberculosis in anti-tumour necrosis factor-treated inflammatory bowel disease patients after the implementation of preventive measures: compliance with recommendations and safety of retreatment. *J. Crohns Colitis* 2016; 10: 1186–93.

14 Bombardier C, Hazlewood GS, Akhavan P et al. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. *J. Rheumatol.* 2012; 39: 1583–602.

15 Shim TS. Diagnosis and treatment of latent tuberculosis infection in patients with inflammatory bowel diseases due to initiation of anti-tumor necrosis factor therapy. *Intest. Res.* 2014; 12: 12–9.

16 British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. *Thorax* 2005; 60: 800–5.

17 Solovic I, Sester M, Gomez-Reino JJ et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. *Eur. Respir. J.* 2010; 36: 1185–206.

18 Chebli JM, Gaburri PD, Chebli LA et al. A guide to prepare patients with inflammatory bowel diseases for anti-TNF-alpha therapy. *Med. Sci. Monit.* 2014; 20: 487–98.

19 Joint Committee for the Revision of Korean Guidelines for Tuberculosis. Seoul and Cheongwon: Korean Centers for Disease Control and Prevention, 2014.

20 Hsia EC, Schluger N, Cushman JJ et al. Interferon-gamma release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. *Arthritis Rheum.* 2012; 64: 2068–77.

21 Denis B, Lefort A, Flipo RM et al. Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-alpha antagonist therapy: safe re-initiation of TNF-alpha blockers after appropriate anti-tuberculous treatment. *Clin. Microbiol. Infect.* 2008; 14: 183–6.

22 Updated recommendations for the use of biological agents for the treatment of rheumatic diseases. Revised 2011. http://www.rheumatology.org.au/downloads/: Australian Rheumatology Association.

23 Mariette X, Salmon D. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. *Ann. Rheum. Dis.* 2003; 62: 791.

24 Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. *Arthritis Rheum.* 2005; 52: 1766–72.

25 Beglinger C, Dudley J, Mottet C et al. Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. *Swiss Med. Wkly.* 2007; 137: 620–2.

26 Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999, and the sections of this statement. *Am. J. Respir. Crit. Care Med.* 2000; 161: S221–S247.

27 Park SJ, Jo KW, Yoo B et al. Comparison of LTBI treatment regimens for patients receiving anti-tumour necrosis factor therapy. *Int. J. Tuberc. Lung Dis.* 2015; 19: 342–8.

28 Ziakas PD, Mylonakis E. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. *Clin. Infect. Dis.* 2009; 49: 1883–9.

29 Al Jahdali HH, Baharoon S, Abba AA et al. Saudi guidelines for testing and treatment of latent tuberculosis infection. *Ann. Saudi Med.* 2010; 30: 38–49.

30 Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection—United States, 2003. *MMWR Morb. Mortal. Wkly Rep.* 2003; 52: 735–9.

31 Sterling TR, Villarino ME, Borisov AS et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. *N. Engl. J. Med.* 2011; 365: 2155–66.

32 Stagg HR, Zenner D, Harris RJ, Munoz L, Lipman MC, Abubaker I. Treatment of latent tuberculosis infection: a network meta-analysis. *Ann. Intern. Med.* 2014; 161: 419–28.

33 Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? *Int. J. Tuberc. Lung Dis.* 1999; 3: 847–50.

34 Gomez-Reino JJ, Carmona L, Angel DM. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. *Arthritis Rheum.* 2007; 57: 756–61.

35 Lee JW, Choi CH, Park JH et al. Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease. *Intest. Res.* 2016; 14: 146–51.

36 Jauregui-Amezaga A, Turon F, Ordas I et al. Risk of developing tuberculosis under anti-TNF therapy in patients at risk of reactivation of latent infection. *Int. J. Tuberc. Lung Dis.* 2013; 7: 208–12.

37 Hernandez-Cruz B, Ponce-de-Leon-Rosas S, Sifuentes-Osorio J, Ponce-de-Leon-Garduno A, Diaz-Joaanen E. Tuberculosis prophylaxis in patients with steroid treatment and systemic rheumatic diseases. A case-control study. *Clin. Exp. Rheumatol.* 1999; 17: 81–7.

38 van der Klooster JM, Bosman RJ, Oudemans-van Straaten HM, van der Spoel JI, Wester JP, Zandstra DF. Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. *Intensive Care Med.* 2003; 29: 2327–9.

39 Connolly LE, Edelstein PH, Ramakrishnan L. Why is long-term therapy required to cure tuberculosis? *PLOS Med.* 2007; 4 e120.

40 Sichletidis L, Settas L, Spyridos D, Chloros D, Patakas D. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. *Int. J. Tuberc. Lung Dis.* 2006; 10: 1127–32.

41 Kwon M, Sung M, Kwon YJ et al. Active tuberculosis risk with tumor necrosis factor inhibitors after treating latent tuberculosis. *J. Clin. Rheumatol.* 2014; 20: 68–73.

42 Higuchi K, Harada N, Mori T. Interferon-gamma responses after isoniazid chemotherapy for latent tuberculosis. *Respirology* 2008; 13: 468–72.

43 Kim KH, Lee SW, Chung WT et al. Serial interferon-gamma release assays for the diagnosis of latent tuberculosis infection in patients treated with immunosuppressive agents. *Korean J. Lab. Med.* 2011; 31: 271–8.

44 Wallis RS, Broder MS, Wong YJ, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. *Clin. Infect. Dis.* 2004; 38: 1261–5.
45 Singh JA, Furst DE, Bharat A et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. (Hoboken) 2012; 64: 625–39.
46 Park JH, Seo GY, Lee JS, Kim TH, Yoo DH. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial. J. Rheumatol. 2009; 36: 2158–63.
47 Chen DY, Shen GH, Chen YM, Chen HH, Hsieh CW, Lan JL. Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFalpha inhibitors: the utility of IFNgamma assay. Ann. Rheum. Dis. 2012; 71: 231–7.
48 Papay P, Primas C, Eser A et al. Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-alpha inhibitors. Aliment. Pharmacol. Ther. 2012; 36: 858–65.
49 Hatzara C, Hadziyannis E, Kandili A et al. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases. Ann. Rheum. Dis. 2015; 74: 1848–53.
50 Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am. J. Respir. Crit. Care Med. 1999; 159: 15–21.
51 Anibarro L, Trigo M, Villaverde C et al. Interferon-gamma release assays in tuberculosis contacts: is there a window period? Eur. Respir. J. 2011; 37: 215–17.
52 Abreu C, Magro F, Santos-Antunes J et al. Tuberculosis in anti-TNF-alpha treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population. J. Crohns Colitis 2013; 7: e486–e492.
53 Abitbol Y, Laharie D, Cosnes J et al. Negative screening does not rule out the risk of tuberculosis in patients with inflammatory bowel disease undergoing Anti-TNF treatment: a descriptive study on the GETAID cohort. J. Crohns Colitis 2016; 10: 1179–85.
54 Debeuckelaere C, De Munter P, Van Hleyenbergh P et al. Tuberculosis infection following anti-TNF therapy in inflammatory bowel disease, despite negative screening. J. Crohns Colitis 2014; 8: 550–7.
55 Newton SM, Mackie SL, Martineau AR et al. Reduction of chemokine secretion in response to mycobacteria in infliximab-treated patients. Clin. Vaccine Immunol. 2008; 15: 506–12.
56 Chakravarty SD, Zhu G, Tsai MC et al. Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs. Infect. Immun. 2008; 76: 916–26.
57 Algood HM, Lin PL, Flynn JL. Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin. Infect. Dis. 2005; 41: S189–S193.
58 Theis VS, Rhodes JM. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment. Pharmacol. Ther. 2008; 27: 19–30.
59 Wallis RS, Kyambahde P, Johnson JL et al. A study of the safety, immunology, virology, and microbiology of adjutecive etanercept in HIV-1-associated tuberculosis. AIDS 2004; 18: 257–64.
60 Mayanja-Kizza H, Jones-Lopez E, Okwera A et al. Immunoadjuvant prednisolone therapy for HIV-associated tuberculosissis: a phase 2 clinical trial in Uganda. J. Infect. Dis. 2005; 191: 856–65.
61 Garcia Vidal C, Rodriguez Fernandez S, Martinez Lacasa J et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin. Infect. Dis. 2005; 40: 756–9.
62 Dhasmana DJ, Dheda K, Ravn P, Wilkinson RJ, Meintjes G. Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and management. Drugs 2008; 68: 191–208.
63 Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 2000; 59: 1341–59.
64 Rivoisy C, Tubach F, Roy C et al. Paradoxical anti-TNF-associated TB worsening: frequency and factors associated with IRIS. Joint Bone Spine 2016; 83: 173–8.
65 Blackmore TK, Manning L, Taylor WJ, Wallis RS. Therapeutic use of infliximab in tuberculosis to control severe paradoxic reaction of the brain and lymph nodes. Clin. Infect. Dis. 2008; 47: e83–e85.